ENMD 2076

Drug Profile

ENMD 2076

Alternative Names: ENMD-2076; ENMD-981693; MKC-1693

Latest Information Update: 20 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Miikana Therapeutics
  • Developer CASI Pharmaceuticals
  • Class Antineoplastics; Piperazines; Pyrazoles; Pyrimidines; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Aurora kinase A inhibitors; Fms-like tyrosine kinase 3 inhibitors; Type 3 fibroblast growth factor receptor antagonists; Vascular endothelial growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer; Multiple myeloma; Liver cancer; Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Breast cancer; Liver cancer
  • Discontinued Acute myeloid leukaemia; Haematological malignancies; Multiple myeloma; Ovarian cancer; Soft tissue sarcoma

Most Recent Events

  • 30 Jun 2018 CASI completes a phase II trial in liver cancer (Late-stage disease) in USA (PO) (NCT02234986)
  • 24 Jun 2018 Biomarkers information updated
  • 05 Dec 2017 Discontinued - Phase-I for Acute myeloid leukaemia in Canada (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top